Randomized, dose-finding phase III study of lithium gamolenate in patients with advanced pancreatic adenocarcinoma


Johnson, C.D., Puntis, M., Davidson, N., Todd, S. and Bryce, R. (2001) Randomized, dose-finding phase III study of lithium gamolenate in patients with advanced pancreatic adenocarcinoma. The British Journal of Surgery, 88, (5), 662-668. (doi:10.1046/j.0007-1323.2001.01770.x).

Download

[img] PDF - Publishers print
Restricted to System admin

Download (1213b) | Request a copy

Description/Abstract

Background: chemotherapy for pancreatic cancer offers small survival benefits and considerable side-effects. Unsaturated fatty acids have an antitumour effect in experimental studies; in phase II studies few side-effects were seen.

Methods: in this group-sequential, open-label, randomized study, 278 patients with a diagnosis of inoperable pancreatic cancer were treated with either oral (700 mg daily for 15 days), low-dose (0,28 g/kg) or high-dose (0,84 g/kg) intravenous lithium gamolenate (LiGLA). The primary endpoint was survival time from randomization using Kaplan-Meier estimates.

Results: median survival after oral and low-dose intravenous treatment was 129 and 121 days respectively. Median survival after high-dose intravenous treatment was 94 days. A good Karnofsky score and the absence of metastases were associated with increased survival. Haemolysis, a marker of rapid infusion, was associated with a median survival time of 249 days in the low-dose intravenous group.

Conclusion: oral or low-dose intravenous LiGLA led to survival times similar to those of other treatments for pancreatic cancer although one subgroup (low-dose intravenous LiGLA with haemolysis) had longer survival. High-dose intravenous treatment appeared to have an adverse effect. Systemic treatment with LiGLA cannot be recommended for the treatment of pancreatic cancer.

Item Type: Article
ISSNs: 0007-1323 (print)
Related URLs:
Subjects: R Medicine > RD Surgery
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions: University Structure - Pre August 2011 > School of Medicine > Cancer Sciences
ePrint ID: 26400
Date Deposited: 24 Apr 2006
Last Modified: 27 Mar 2014 18:15
URI: http://eprints.soton.ac.uk/id/eprint/26400

Actions (login required)

View Item View Item